San Francisco, California, USA, October 8, 2026
Vir Biotechnology, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VIR-5500, an investigational prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN® dual-masked T-cell engager for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). The candidate is being co-developed by Vir Biotechnology and Astellas Pharma Inc. through a global strategic collaboration. The regulatory designation is intended to facilitate the development and review of therapies for serious conditions that address unmet medical needs. The announcement, made on October 8, 2026, represents an important milestone as the companies prepare for the next stage of clinical development. VIR-5500 is being evaluated for patients with advanced prostate cancer whose disease has progressed despite previous treatments, a population that continues to require additional therapeutic options. The companies anticipate initiating pivotal Phase 3 development in 2027, subject to ongoing clinical progress and regulatory discussions.
VIR-5500 Targets PSMA in Advanced Prostate Cancer
VIR-5500 is designed to direct the body’s immune system toward cancer cells expressing prostate-specific membrane antigen (PSMA), a protein commonly found at elevated levels on prostate cancer cells. The investigational medicine belongs to a class of therapies known as T-cell engagers (TCEs), which are engineered to bring T cells into proximity with tumor cells and promote immune-mediated cancer cell destruction. VIR-5500 incorporates Vir’s PRO-XTEN dual-masking technology, which is designed to keep the molecule masked until it encounters conditions associated with the tumor microenvironment. This approach aims to improve tumor-directed activity while limiting unwanted immune activation in healthy tissues. By combining PSMA targeting with conditional activation, the candidate is being investigated as a potential treatment for advanced disease. The technology is intended to balance antitumor activity with tolerability, an important consideration for T-cell-engaging medicines. However, the proposed advantages must be established through clinical testing, and the candidate remains investigational. The Fast Track designation supports further development but does not establish that VIR-5500 is safe or effective for routine clinical use.
Fast Track Designation Supports Clinical Development
The FDA’s Fast Track program is intended to facilitate the development and expedite the review of medicines designed to treat serious conditions and address unmet medical needs. The designation can provide opportunities for more frequent communication with the agency and may support eligibility for certain expedited development and review pathways when their requirements are met. For VIR-5500, the designation applies to late-line metastatic castration-resistant prostate cancer. The candidate is currently being evaluated in a Phase 1 clinical study that includes six dose-expansion cohorts. These cohorts assess VIR-5500 as a single agent in patients who have not received taxane chemotherapy or radioligand therapy, as well as those previously exposed to radioligand treatment. Additional cohorts investigate combinations with enzalutamide, docetaxel and darolutamide in different prostate cancer settings. Earlier Phase 1 findings reported by the company indicated that VIR-5500 was generally well tolerated and demonstrated preliminary antitumor activity in patients with mCRPC. These early findings provide a rationale for continued investigation, but larger, controlled trials will be needed to establish the treatment’s clinical benefit and characterize its safety profile more fully.
Advertisement
Vir and Astellas Prepare for Phase 3 Trials in 2027
Vir Biotechnology and Astellas are collaborating to advance VIR-5500 through clinical development, combining their expertise in biotechnology, oncology research and drug development. The companies expect to begin pivotal Phase 3 trials in 2027, depending on the outcome of ongoing research and development planning. These studies are expected to provide more definitive evidence about the candidate’s efficacy, safety and potential role in treating advanced prostate cancer. Metastatic castration-resistant prostate cancer is particularly challenging because the disease continues to progress despite treatments designed to suppress androgen signaling. Patients who have exhausted multiple therapies may have limited options, highlighting the need for new approaches that use different biological mechanisms. VIR-5500 represents an investigational immunotherapy strategy designed to harness T cells against PSMA-expressing tumors. Its future clinical value will depend on the results of ongoing and planned trials, including assessments of response rates, response durability, adverse events and other clinically meaningful outcomes. The FDA Fast Track designation marks progress in the development program, while further clinical evidence and regulatory review will determine whether VIR-5500 can eventually become a treatment option for patients with advanced prostate cancer.
Source: BioMarin press release
